Tumor suppressor immune gene therapy to reverse immunotherapy resistance.
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
28
01
2021
accepted:
13
07
2021
revised:
21
06
2021
pubmed:
6
8
2021
medline:
23
6
2022
entrez:
5
8
2021
Statut:
ppublish
Résumé
While immune checkpoint inhibitors are becoming a standard of care for multiple types of cancer, the majority of patients do not respond to this form of immunotherapy. New approaches are required to overcome resistance to immunotherapies. We investigated the effects of adenoviral p53 (Ad-p53) gene therapy in combination with immune checkpoint inhibitors and selective IL2 or IL15 CD122/132 agonists in the aggressive B16F10 tumor model resistant to immunotherapies. To assess potential mechanisms of action, pre- and post- Ad-p53 treatment biopsies were evaluated for changes in gene-expression profiles by Nanostring IO 360 assays. The substantial synergy of "triplet" Ad-p53 + CD122/132 + anti-PD-1 therapy resulted in potential curative effects associated with the complete tumor remissions of both the primary and contralateral tumors. Interestingly, contralateral tumors, which were not injected with Ad-p53 showed robust abscopal effects resulting in statistically significant decreases in tumor size and increased survival (p < 0.001). None of the monotherapies or doublet treatments induced the complete tumor regressions. Ad-p53 treatment increased interferon, CD8 These results imply the ability of Ad-p53 to induce efficacious local and systemic antitumor immune responses with the potential to reverse resistance to immune checkpoint inhibitor therapy when combined with CD122/132 agonists and immune checkpoint blockade. Our findings further imply that Ad-p53 has multiple complementary immune mechanisms of action, which support future clinical evaluation of triplet Ad-p53, CD122/132 agonist, and immune checkpoint inhibitor combination treatment.
Sections du résumé
BACKGROUND
While immune checkpoint inhibitors are becoming a standard of care for multiple types of cancer, the majority of patients do not respond to this form of immunotherapy. New approaches are required to overcome resistance to immunotherapies.
METHODS
We investigated the effects of adenoviral p53 (Ad-p53) gene therapy in combination with immune checkpoint inhibitors and selective IL2 or IL15 CD122/132 agonists in the aggressive B16F10 tumor model resistant to immunotherapies. To assess potential mechanisms of action, pre- and post- Ad-p53 treatment biopsies were evaluated for changes in gene-expression profiles by Nanostring IO 360 assays.
RESULTS
The substantial synergy of "triplet" Ad-p53 + CD122/132 + anti-PD-1 therapy resulted in potential curative effects associated with the complete tumor remissions of both the primary and contralateral tumors. Interestingly, contralateral tumors, which were not injected with Ad-p53 showed robust abscopal effects resulting in statistically significant decreases in tumor size and increased survival (p < 0.001). None of the monotherapies or doublet treatments induced the complete tumor regressions. Ad-p53 treatment increased interferon, CD8
CONCLUSIONS
These results imply the ability of Ad-p53 to induce efficacious local and systemic antitumor immune responses with the potential to reverse resistance to immune checkpoint inhibitor therapy when combined with CD122/132 agonists and immune checkpoint blockade. Our findings further imply that Ad-p53 has multiple complementary immune mechanisms of action, which support future clinical evaluation of triplet Ad-p53, CD122/132 agonist, and immune checkpoint inhibitor combination treatment.
Identifiants
pubmed: 34349241
doi: 10.1038/s41417-021-00369-7
pii: 10.1038/s41417-021-00369-7
pmc: PMC9209327
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
825-834Informations de copyright
© 2021. The Author(s).
Références
Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2:e192535.
doi: 10.1001/jamanetworkopen.2019.2535
Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19:694–704.
doi: 10.1016/S1470-2045(18)30148-7
Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, et al. Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02). Cancer Discov. 2020;10:1158–73.
doi: 10.1158/2159-8290.CD-19-1510
Ju G, Heaton KM, Grimm EA. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine Secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res. 1993;53:2597–602.
pubmed: 8495422
Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature. 2012;484:529–33.
doi: 10.1038/nature10975
Rhode PR, Egan JO, Xu W, Hong H, Webb GM, Chen X, et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res. 2016;4:49–60.
doi: 10.1158/2326-6066.CIR-15-0093-T
Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22:680–90.
doi: 10.1158/1078-0432.CCR-15-1631
Olivier M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, et al. Recent advances in p53 research: An interdisciplinary perspective. Cancer Gene Ther. 2009;16:1–12.
doi: 10.1038/cgt.2008.69
Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, et al. Use of wild‐type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinogenesis. 1995;14:275–85.
doi: 10.1002/mc.2940140408
Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C, et al. Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res. 2009;15:7719–25.
doi: 10.1158/1078-0432.CCR-09-1044
Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1994;1:5–13.
pubmed: 7621238
Senzer N, Nemunaitis J, Nemunaitis M, Lamont J, Gore M, Gabra H, et al. p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Therapeutics. 2007;6:1478–82.
doi: 10.1158/1535-7163.MCT-07-0125
Sobol RE, Guan YS, Li LJ, Zhang WW, Peng Z, Menander KB, et al. Tp53 gene therapy for cancer treatment and prevention. New York: Springer; 2013. p. 189–208.
Dubois S, Patel HJ, Zhang M, Waldmann TA, Müller JR. Preassociation of IL-15 with IL-15R$α$-IgG1-Fc enhances its activity on proliferation of NK and CD8 + /CD44 high T cells and its antitumor action. J Immunol. 2008;180:2099–106.
doi: 10.4049/jimmunol.180.4.2099
Desbois M, Le VuP, Coutzac C, Marcheteau E, Béal C, Terme M, et al. IL-15 Trans -signaling with the superagonist RLI promotes effector/memory CD8 + T cell responses and enhances antitumor activity of PD-1 antagonists. J Immunol. 2016;197:168–78.
doi: 10.4049/jimmunol.1600019
Gillies SD, Lan Y, Hettmann T, Brunkhorst B, Sun Y, Mueller SO, et al. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res. 2011;17:3673–85.
doi: 10.1158/1078-0432.CCR-10-2921
Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, et al. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer. 2018;6:1–17.
doi: 10.1186/s40425-018-0367-1
Ayers M, Ribas A, McClanahan TK, Ayers M, Lunceford J, Nebozhyn M, et al. blockade IFN- $γ$ – related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127:2930–40.
doi: 10.1172/JCI91190
Dzinic SH, Bernardo MM, Oliveira DSM, Wahba M, Sakr W, Sheng S. Tumor suppressor maspin as a modulator of host immune response to cancer. Bosn J Basic Med Sci. 2015;15:1–6.
doi: 10.17305/bjbms.2015.783
Dzinic SH, Chen K, Thakur A, Kaplun A, Daniel Bonfil R, Li X, et al. Maspin expression in prostate tumor elicits host anti-tumor immunity. Oncotarget. 2014;5:11225–36.
doi: 10.18632/oncotarget.2615
Fijneman RJA, Peham JR, van de Wiel MA, Meijer GA, Matise I, Velcich A, et al. Expression of Pla2g2a prevents carcinogenesis in Muc2-deficient mice. Cancer Sci. 2008;99:2113–9.
doi: 10.1111/j.1349-7006.2008.00924.x
Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Ming HL, et al. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel $β$-catenin/TCF target gene. Cancer Res. 2008;68:4277–86.
doi: 10.1158/0008-5472.CAN-07-6517
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–8.
doi: 10.1038/nature25501
Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic $β$-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231–5.
doi: 10.1038/nature14404
Dou A, Wang Z, Zhang N, Liu J. Loss of reelin suppresses cell survival and mobility in non-Hodgkin lymphoma. Oncol Rep. 2017;37:3572–80.
doi: 10.3892/or.2017.5626
Garcia-Vallejo JJ, van Kooyk Y. DC-SIGN: the strange case of Dr. Jekyll and Mr. Hyde. Immunity. 2015;42:983–5.
doi: 10.1016/j.immuni.2015.05.021
Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Östling J, et al. Reprogramming yumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 2016;15:2000–11.
doi: 10.1016/j.celrep.2016.04.084
Martínez-Ramírez I, Del-Castillo-Falconi V, Mitre-Aguilar IB, Amador-Molina A, Carrillo-García A, Langley E, et al. SOX2 as a new regulator of HPV16 transcription. Viruses. 2017;9:1–17.
doi: 10.3390/v9070175
Sobol RE, Menander KB, Chada S, Wiederhold D, Sellman B, Talbott M, et al. Analysis of adenoviral p53 gene therapy clinical trials in recurrent head and neck squamous cell carcinoma. Front Oncol. 2021;11:645745.
doi: 10.3389/fonc.2021.645745
Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W-J, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol. 2015;33:3001.
doi: 10.1200/jco.2015.33.15_suppl.3001
Brenner AK, Bruserud Ø. S100 proteins in acute myeloid leukemia. Neoplasia. 2018;20:1175–86.
doi: 10.1016/j.neo.2018.09.007
Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respiratory Crit Care Med. 2006;173:781–92.
doi: 10.1164/rccm.200509-1518OC
Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med. 2008;5:373–80.
doi: 10.1371/journal.pmed.0050062
Keane MP. The role of chemokines and cytokines in lung fibrosis. Eur Respir Rev. 2008;17:151–6.
doi: 10.1183/09059180.00010908
Korthagen NM, Van Moorsel CHM, Kazemier KM, Ruven HJT, Grutters JC. IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. Immunogenetics. 2012;64:371–7.
doi: 10.1007/s00251-012-0604-6
Dzinic SH, Bernardo MM, Li X, Fernandez-Valdivia R, Ho YS, Mi QS, et al. An essential role of maspin in embryogenesis and tumor suppression. Cancer Res. 2017;77:886–96.
doi: 10.1158/0008-5472.CAN-16-2219
Sathyanarayana UG, Padar A, Huang CX, Suzuki M, Shigematsu H, Bekele BN, et al. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma. Clin Cancer Res. 2003;9:6389–94.
pubmed: 14695139
Huang Y, Li X, Jiang J, Frank SJ. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene. 2006;25:7565–76.
doi: 10.1038/sj.onc.1209740
Segovia J, Zarco N. Gas1 is a pleiotropic regulator of cellular functions: from embryonic development to molecular actions in cancer gene therapy. Mini-Rev Medicinal Chem. 2014;14:1139–47.
doi: 10.2174/1389557514666141127142301
Zhou X, Hao Q, Liao P, Luo S, Zhang M, Hu G, et al. Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator. eLife. 2016;5:e15099.
doi: 10.7554/eLife.15099